Metrics to compare | 4598 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship4598PeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.9x | −9.6x | −0.4x | |
PEG Ratio | −0.04 | −0.38 | 0.00 | |
Price/Book | −8.0x | 3.4x | 2.6x | |
Price / LTM Sales | - | 18.4x | 3.1x | |
Upside (Analyst Target) | - | 120.3% | 48.9% | |
Fair Value Upside | Unlock | 1.3% | 6.2% | Unlock |
Delta-Fly Pharma, Inc. develops anticancer drugs. It develops DFP-10917 that is in phase 1/2 clinical trial in the United States and phase I trial in Japan for the treatment of relapsed/refractory acute myeloid leukemia; DFP-14323, which is in phase III clinical trial to treat lung cancer; DFP-17729 that is in phase I/II clinical trials for the treatment of solid cancer; DFP-11207, which has completed phase I clinical trial to treat pancreatic cancer; DFP-14927 that is in phase I for the treatment of hematologic cancer; and DFP-10825, which is in preclinical trial to treat gastric/ovarian cancer. The company was incorporated in 2010 and is headquartered in Tokushima, Japan.